J. Strosberg digs into results from first randomised study with radiolabelled somatostatin analogue peptides in patients with midgut neuroendocrine tumours (NETs). The primary endpoint of progression-free survival is longer at interim analysis with also favourable overall survival and response rate, the data to be confirmed in final analysis. Renal toxicity is tolerable; myelosuppression is in general mild, however, there is a concern of later myelodysplastic syndrome and leukaemia, currently predicted to be low.

Oncology Meeting Resources

Major Sponsors

AstraZeneca Janssen Servier

Main Sponsors

Amgen Astellas Bayer Healthcare Boehringer Ingelheim Daiichi Sankyo Genomic Health Inc. Lilly Oncology Nutricia Roche